Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
PHASE1CompletedINTERVENTIONAL
Enrollment
13
Participants
Timeline
Start Date
October 3, 2022
Primary Completion Date
November 15, 2023
Study Completion Date
November 15, 2023
Conditions
Granuloma Annulare
Interventions
DRUG
AC-1101
For each patient, once daily (QD)
Trial Locations (1)
06519
Yale Center for Clinical Investigation, New Haven
All Listed Sponsors
lead
TWi Biotechnology, Inc.
INDUSTRY
NCT05580042 - Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare | Biotech Hunter | Biotech Hunter